Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Pharmacokinetics And Pharmacodynamics - NAPLEX

  1. A 62-year-old female (weight 75 kg, height 166 cm) with chronic atrial fibrillation is treated with diltiazem and metoprolol and presents with dizziness and near-syncope. Current medications: diltiazem extended-release 240 mg by mouth daily, metoprolol tartrate 50 mg by mouth twice daily, apixaban 5 mg by mouth twice daily. Vitals: heart rate 42 beats/min, blood pressure 92/56 mmHg. Labs: serum creatinine 0.9 mg/dL, aspartate aminotransferase 20 U/L, alanine aminotransferase 18 U/L. Allergies: none. Therapeutic goal: adequate rate control without symptomatic bradycardia. Which pharmacodynamic effect is responsible for the patient's symptoms?
    Answer: Additive atrioventricular nodal blockade causing bradycardia and hypotension This question tests the pharmacodynamic concept of additive negative chronotropic effects in rate control. The key patient-specific factor is the patient's atrial fibrillation managed with dual AV nodal blockers, leading to excessive bradycardia. Additive atrioventricular nodal blockade causing bradycardia and hypotension is the best choice as it explains symptoms from combined calcium channel and beta blockade. Competitive antagonism causing tachycardia is opposite; induction of apixaban metabolism causing bleeding is unrelated; increased renal clearance of metoprolol is false. A transferable clinical pearl is avoiding full doses of non-dihydropyridine CCBs with beta-blockers due to syncope risk. Decision frameworks include ECG monitoring and dose titration targeting HR 60-80 bpm in AF.
  2. A 64-year-old female (weight 60 kg, height 158 cm) with chronic obstructive pulmonary disease is started on theophylline for persistent symptoms. Current medications: theophylline extended-release 300 mg by mouth every 12 hours, albuterol inhaler as needed. She reports quitting smoking 10 days ago (previously 1 pack/day). Labs: serum creatinine 0.8 mg/dL, aspartate aminotransferase 24 U/L, alanine aminotransferase 21 U/L; theophylline level 18 mcg/mL (goal 10–20 mcg/mL) with nausea and insomnia. Allergies: none. Therapeutic goal: symptom control with theophylline in goal range and minimal adverse effects. Which pharmacokinetic parameter is most affected in this patient?
    Answer: Decreased hepatic clearance of theophylline after smoking cessation This question tests the pharmacokinetic concept of enzyme induction effects on drug clearance. The key patient-specific factor is the patient's recent smoking cessation, reducing CYP1A2 induction and theophylline metabolism. Decreased hepatic clearance of theophylline after smoking cessation is the best choice as it explains elevated levels and toxicity from loss of induction. Increased renal clearance is incorrect as smoking does not affect it; decreased bioavailability is false; increased volume of distribution is unrelated. A transferable clinical pearl is theophylline's half-life increases 30-50% post-cessation, requiring dose reduction. Monitoring strategies include checking levels 1-2 weeks after lifestyle changes, targeting 8-15 mcg/mL for COPD.
  3. A 65-year-old male (weight 80 kg, height 175 cm) with epilepsy is receiving phenytoin extended-release 300 mg by mouth once daily; other medications: omeprazole 20 mg daily; allergies: none. Labs: serum creatinine 0.9 mg/dL, aspartate aminotransferase 22 U/L, alanine aminotransferase 18 U/L, albumin 2.0 g/dL (low), total phenytoin concentration 8 mcg/mL (reference 10–20 mcg/mL). Therapeutic goal: seizure control without toxicity. Which pharmacokinetic parameter is most affected in this patient, leading to potential misinterpretation of the measured phenytoin level?
    Answer: Increased fraction unbound due to low albumin, making total concentration appear falsely low This question tests understanding of protein binding and its effect on phenytoin pharmacokinetics and therapeutic drug monitoring. The key patient-specific factor is hypoalbuminemia (albumin 2.0 g/dL), which significantly affects phenytoin's highly protein-bound nature (normally ~90% bound). Option A is correct because low albumin increases the fraction unbound (free) phenytoin, making the total concentration appear falsely low while the pharmacologically active free concentration may actually be therapeutic or even elevated. Option B is incorrect because normal serum creatinine doesn't indicate increased renal clearance, and phenytoin is primarily hepatically metabolized anyway. Option C is wrong because omeprazole doesn't significantly affect phenytoin bioavailability, and this wouldn't make free concentration falsely high. Option D misunderstands the concept - while low albumin does increase volume of distribution for total drug, it's the increased fraction unbound that makes total levels misleading, not the Vd change itself. The clinical pearl is to calculate corrected phenytoin levels using the Sheiner-Tozer equation: Corrected phenytoin = Measured phenytoin / [(0.2 × albumin) + 0.1], or preferably measure free phenytoin levels directly in hypoalbuminemic patients.
  4. A 59-year-old female (weight 72 kg, height 162 cm) with rheumatoid arthritis is stable on methotrexate but develops mouth sores and fatigue after starting a new medication. Current medications: methotrexate 15 mg by mouth once weekly, folic acid 1 mg by mouth daily, pantoprazole 40 mg by mouth daily (started 3 weeks ago), naproxen 500 mg by mouth twice daily. Labs: serum creatinine 1.3 mg/dL (baseline 0.9 mg/dL), aspartate aminotransferase 45 U/L (high; normal <40), alanine aminotransferase 52 U/L (high; normal <40). Allergies: none. Therapeutic goal: control rheumatoid arthritis while preventing methotrexate toxicity. Which drug interaction is most likely affecting the patient's drug levels?
    Answer: Pantoprazole decreases renal clearance of methotrexate, increasing exposure This question tests the pharmacokinetic concept of drug-drug interactions affecting renal elimination. The key patient-specific factor is the patient's mild renal impairment with serum creatinine 1.3 mg/dL, potentiating methotrexate accumulation. Pantoprazole decreases renal clearance of methotrexate, increasing exposure is the best choice as PPIs inhibit organic anion transporters, explaining toxicity symptoms and elevated liver enzymes. Folic acid inhibiting absorption is incorrect as it mitigates toxicity; naproxen inducing metabolism is false; methotrexate increasing pantoprazole metabolism does not occur. A transferable clinical pearl is high-dose methotrexate requires leucovorin rescue and hydration to enhance clearance. Decision frameworks include holding MTX if ALT/AST >3x upper limit and monitoring levels with interactors.
  5. A 70-year-old male (weight 92 kg, height 178 cm) with heart failure and atrial fibrillation is on digoxin 0.25 mg by mouth daily, furosemide 40 mg by mouth twice daily, and carvedilol 25 mg by mouth twice daily; allergies: none. He reports nausea and yellow-green vision changes. Labs: serum creatinine 1.6 mg/dL, potassium 3.0 mEq/L (low), aspartate aminotransferase 30 U/L, alanine aminotransferase 26 U/L, digoxin level 2.4 ng/mL (typical goal 0.5–0.9 ng/mL in heart failure). Therapeutic goal: symptom control of heart failure and rate control while avoiding toxicity. Which pharmacodynamic effect is responsible for the patient's symptoms?
    Answer: Inhibition of Na+/K+-ATPase leading to increased intracellular calcium and enhanced automaticity This question tests understanding of digoxin's pharmacodynamic mechanism and toxicity manifestations. The key patient-specific factors are elevated digoxin level (2.4 ng/mL), hypokalemia (3.0 mEq/L), and renal impairment affecting digoxin clearance. Option B is correct because digoxin inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which triggers the Na+/Ca2+ exchanger to increase intracellular calcium, causing enhanced automaticity and the classic toxicity symptoms of nausea and visual disturbances (xanthopsia - yellow-green vision). Option A is incorrect because while digoxin can cause bradycardia, this is not through beta-blockade but through vagal effects and AV node depression. Option C is wrong because digoxin doesn't directly antagonize L-type calcium channels. Option D is incorrect as digoxin doesn't stimulate renin release or cause vasoconstriction through this mechanism. The clinical pearl is that hypokalemia potentiates digoxin toxicity by increasing digoxin binding to Na+/K+-ATPase, and visual disturbances (especially color vision changes) are pathognomonic for digoxin toxicity. Always check potassium levels and renal function when monitoring digoxin therapy.
  6. A 40-year-old male (weight 76 kg, height 180 cm) with HIV is on antiretroviral therapy and develops uncontrolled hyperlipidemia. Current medications: atazanavir/cobicistat 300/150 mg by mouth daily, emtricitabine/tenofovir alafenamide 200/25 mg by mouth daily, simvastatin 40 mg by mouth nightly (recently started by outside provider). Labs: aspartate aminotransferase 38 U/L, alanine aminotransferase 41 U/L (slightly high; normal <40), serum creatinine 0.9 mg/dL; creatine kinase 950 U/L (high; normal <200) with muscle pain. Allergies: none. Therapeutic goal: lipid lowering without statin toxicity. Which drug interaction is most likely affecting the patient's drug levels?
    Answer: Cobicistat inhibits CYP3A4, increasing simvastatin concentrations and myopathy risk This question tests the pharmacokinetic concept of CYP3A4 inhibition increasing statin exposure. The key patient-specific factor is the patient's HIV therapy with cobicistat, a strong CYP3A4 inhibitor elevating simvastatin levels. Cobicistat inhibits CYP3A4, increasing simvastatin concentrations and myopathy risk is the best choice as it explains elevated CK and muscle pain from interaction. Atazanavir inducing CYP3A4 is incorrect as it inhibits; simvastatin decreasing tenofovir absorption is false; tenofovir inhibiting simvastatin elimination is not accurate. A transferable clinical pearl is limiting simvastatin to 20 mg with moderate inhibitors, but contraindicating with strong ones like cobicistat. Decision frameworks include checking Liverpool HIV interactions database for ART-statin compatibility.
  7. A 68-year-old male (weight 72 kg, height 174 cm) with chronic kidney disease and neuropathic pain is prescribed gabapentin. Current medications: gabapentin 600 mg by mouth three times daily, duloxetine 60 mg by mouth daily. Labs: serum creatinine 2.3 mg/dL (estimated creatinine clearance 25 mL/min), aspartate aminotransferase 21 U/L, alanine aminotransferase 18 U/L. He reports dizziness and somnolence. Allergies: none. Therapeutic goal: reduce neuropathic pain while minimizing adverse effects. What is the appropriate dose adjustment given the patient's renal function?
    Answer: Reduce gabapentin total daily dose and/or extend dosing interval (e.g., 300 mg once to twice daily) based on creatinine clearance This question tests the pharmacokinetic concept of renal drug clearance and dose adjustment in impaired kidney function. The key patient-specific factor is the patient's reduced creatinine clearance of 25 mL/min, indicating moderate-to-severe chronic kidney disease, which impairs the elimination of renally cleared drugs like gabapentin. Option B is the best choice because gabapentin is primarily excreted unchanged by the kidneys, and reducing the dose or extending the interval prevents drug accumulation and minimizes adverse effects such as dizziness and somnolence. Option A is incorrect as gabapentin is not hepatically cleared but renally eliminated, so continuing the current dose would lead to toxicity in renal impairment; option C is suboptimal because increasing the dose would exacerbate side effects without addressing tolerance, which is not indicated here. Option D is wrong because extended-release gabapentin still requires renal dose adjustment, and switching without modification could maintain high exposure. A clinical pearl is that for renally cleared drugs, dose adjustments are guided by creatinine clearance using formulas like Cockcroft-Gault. Always monitor for adverse effects and consider therapeutic drug monitoring when available to optimize dosing in renal impairment.
  8. A 66-year-old male (weight 85 kg, height 172 cm) with deep vein thrombosis is started on enoxaparin. Medical history: chronic kidney disease stage 4. Current medications: enoxaparin 1 mg/kg subcutaneously every 12 hours, aspirin 81 mg by mouth daily. Labs: serum creatinine 2.8 mg/dL (estimated creatinine clearance 22 mL/min), platelets 210,000/mm3^3, aspartate aminotransferase 27 U/L, alanine aminotransferase 25 U/L. Anti-factor Xa level (drawn 4 hours after the 3rd dose) is 1.4 IU/mL (goal 0.6–1.0 IU/mL for twice-daily treatment dosing). Allergies: none. Therapeutic goal: treat thrombosis while minimizing bleeding. What is the appropriate dose adjustment given the patient's renal function?
    Answer: Change enoxaparin to 1 mg/kg subcutaneously every 24 hours This question tests the pharmacokinetic concept of renal dose adjustment for anticoagulants to prevent accumulation. The key patient-specific factor is the patient's creatinine clearance of 22 mL/min, reducing enoxaparin clearance and elevating anti-Xa levels. Changing enoxaparin to 1 mg/kg subcutaneously every 24 hours is the best choice as it follows guidelines for CrCl <30 mL/min to minimize bleeding risk while treating DVT. Continuing every 12 hours ignores accumulation; increasing to 1.5 mg/kg is dangerous with high anti-Xa; switching to prophylaxis dosing under-treats thrombosis. A transferable clinical pearl is enoxaparin's half-life doubles in severe renal impairment, necessitating interval extension. Monitoring strategies include anti-Xa levels 4 hours post-dose, targeting 0.5-1.0 IU/mL for once-daily dosing.
  9. A 61-year-old male (weight 82 kg, height 177 cm) with a history of pulmonary embolism is switched from warfarin to rivaroxaban. Medical history: chronic kidney disease stage 3. Current medications: rivaroxaban 20 mg by mouth daily with evening meal, verapamil extended-release 240 mg by mouth daily, lisinopril 20 mg by mouth daily. Labs: serum creatinine 1.7 mg/dL (estimated creatinine clearance 38 mL/min), aspartate aminotransferase 29 U/L, alanine aminotransferase 27 U/L, international normalized ratio 1.1. Allergies: none. Therapeutic goal: prevent recurrent venous thromboembolism with minimized bleeding risk. What is the appropriate dose adjustment given the patient's renal function?
    Answer: Decrease rivaroxaban to 15 mg by mouth daily with food This question tests the pharmacokinetic concept of renal dose adjustment for direct oral anticoagulants. The key patient-specific factor is the patient's creatinine clearance of 38 mL/min, indicating moderate impairment reducing rivaroxaban elimination. Decreasing rivaroxaban to 15 mg by mouth daily with food is the best choice as it follows labeling for CrCl 15-50 mL/min to prevent accumulation while ensuring efficacy. Continuing 20 mg ignores renal guidelines; increasing to 30 mg is inappropriate with verapamil interaction increasing exposure; changing to 10 mg is not standard. A transferable clinical pearl is rivaroxaban's renal clearance is ~33%, necessitating dose reduction below 50 mL/min. Monitoring strategies include annual CrCl reassessment and bleeding/ thrombosis surveillance.
  10. A 72-year-old male (weight 75 kg, height 172 cm) with bipolar disorder and chronic kidney disease is taking lithium carbonate 300 mg by mouth three times daily, hydrochlorothiazide 25 mg by mouth daily started 1 week ago, and levothyroxine 75 mcg by mouth daily; allergies: none. He presents with tremor, diarrhea, and confusion. Labs: serum creatinine 1.8 mg/dL, sodium 132 mEq/L (low), aspartate aminotransferase 20 U/L, alanine aminotransferase 18 U/L, lithium level 1.9 mEq/L (typical maintenance goal 0.6–1.2 mEq/L). Therapeutic goal: stabilize mood while avoiding toxicity. Which drug interaction is most likely affecting the patient's drug levels?
    Answer: Hydrochlorothiazide decreases lithium renal clearance via increased proximal sodium (and lithium) reabsorption This question tests understanding of lithium pharmacokinetics and drug interactions affecting renal clearance. The key patient-specific factors are baseline renal impairment, recent thiazide diuretic initiation, hyponatremia, and lithium toxicity symptoms with elevated level. Option B is correct because hydrochlorothiazide decreases lithium renal clearance through a well-established mechanism: thiazides cause mild volume depletion, triggering compensatory increased proximal tubule sodium reabsorption, and since lithium is reabsorbed alongside sodium, this increases lithium reabsorption and decreases its clearance. Option A is incorrect because HCTZ decreases, not increases, lithium clearance, and urine alkalinization isn't the mechanism. Option C is wrong because levothyroxine doesn't significantly affect lithium metabolism. Option D incorrectly suggests lithium affects HCTZ metabolism rather than the reverse. The clinical pearl is that thiazide and loop diuretics significantly increase lithium levels (thiazides more so), requiring 25-50% lithium dose reduction and close monitoring when initiating diuretics; potassium-sparing diuretics like amiloride are safer alternatives if diuresis is needed.
  11. A 50-year-old male (weight 88 kg, height 179 cm) with status epilepticus is started on continuous infusion midazolam in the intensive care unit and is later difficult to wean off sedation. Medical history: alcoholic cirrhosis. Current medications: midazolam infusion, lactulose 20 g by mouth three times daily, rifaximin 550 mg by mouth twice daily. Labs: total bilirubin 4.2 mg/dL (high), albumin 2.5 g/dL (low), international normalized ratio 2.0 (high), aspartate aminotransferase 85 U/L (high), alanine aminotransferase 70 U/L (high), serum creatinine 0.9 mg/dL. Allergies: none. Therapeutic goal: achieve seizure control with safe sedation and timely awakening. Which pharmacokinetic parameter is most affected in this patient?
    Answer: Decreased hepatic clearance leading to prolonged midazolam effect This question tests the pharmacokinetic concept of altered hepatic metabolism in liver disease. The key patient-specific factor is the patient's alcoholic cirrhosis with elevated bilirubin and INR, impairing midazolam clearance. Decreased hepatic clearance leading to prolonged midazolam effect is the best choice as it explains difficult weaning from sedation due to reduced CYP3A4 activity in cirrhosis. Increased renal clearance is incorrect as midazolam is hepatically cleared; increased first-pass metabolism decreases exposure is false; decreased oral absorption is not relevant for IV use. A transferable clinical pearl is benzodiazepine half-life can triple in cirrhosis, favoring short-acting agents like lorazepam. Monitoring strategies include using BIS scores for sedation depth and adjusting infusions based on Child-Pugh classification.
  12. Absorbed fraction is 0.8; oral F is 0.5. Hepatic extraction ratio? (Assume no gut metabolism.)
    Answer: 0.375 With no gut metabolism, oral F = absorbed fraction times (1 - hepatic extraction ratio). So 0.5 = 0.8 x (1 - Eh), giving 1 - Eh = 0.625 and Eh = 0.375. The tempting wrong answer is 0.625, which is the fraction escaping the liver, not the extraction ratio.
  13. A 58-year-old female (weight 70 kg, height 165 cm) with a mechanical mitral valve is taking warfarin 5 mg by mouth daily (stable for months), amiodarone 200 mg by mouth daily started 10 days ago, and atorvastatin 40 mg nightly; allergies: none. Labs: international normalized ratio 5.2 (goal 2.5–3.5), serum creatinine 0.8 mg/dL, aspartate aminotransferase 24 U/L, alanine aminotransferase 20 U/L; no signs of bleeding. Therapeutic goal: maintain INR in target range and prevent thrombosis. Which drug interaction is most likely affecting the patient's drug levels?
    Answer: Amiodarone inhibits CYP2C9, increasing warfarin exposure and increasing INR This question tests understanding of cytochrome P450-mediated drug interactions affecting warfarin pharmacokinetics. The key patient-specific factor is the recent addition of amiodarone to stable warfarin therapy, causing a dramatic INR increase from therapeutic range to 5.2. Option B is correct because amiodarone is a potent inhibitor of multiple CYP enzymes including CYP2C9, which metabolizes the more potent S-warfarin enantiomer, leading to decreased warfarin clearance, increased warfarin exposure, and elevated INR. Option A is incorrect because amiodarone inhibits, not induces, CYP2C9. Option C is wrong because atorvastatin's P-glycoprotein effects are minimal for warfarin, and induction would decrease, not increase, INR. Option D is nonsensical as warfarin doesn't affect amiodarone absorption, and the mechanism described doesn't match the observation. The clinical pearl is that amiodarone-warfarin interaction typically requires empiric warfarin dose reduction of 30-50% when initiating amiodarone, with close INR monitoring for several weeks as amiodarone's long half-life means the interaction develops gradually and persists long after discontinuation.
  14. A 78-year-old female (weight 52 kg, height 160 cm) with atrial fibrillation and chronic kidney disease stage 4 is taking apixaban 5 mg by mouth twice daily, amiodarone 200 mg by mouth daily, and lisinopril 10 mg by mouth daily; allergies: penicillin (rash). Labs: serum creatinine 2.3 mg/dL, aspartate aminotransferase 28 U/L, alanine aminotransferase 24 U/L, international normalized ratio 1.1. Therapeutic goal: stroke prevention while minimizing bleeding risk. What is the appropriate dose adjustment given the patient's renal function and characteristics?
    Answer: Reduce apixaban to 2.5 mg by mouth twice daily This question tests the pharmacokinetic principle of renal dose adjustment for direct oral anticoagulants in patients with multiple risk factors for bleeding. The key patient-specific factors affecting apixaban pharmacokinetics are severe renal impairment (CrCl likely <25 mL/min based on Cockcroft-Gault), advanced age (78 years), and low body weight (52 kg). Option B is correct because apixaban requires dose reduction to 2.5 mg twice daily when patients have at least 2 of 3 criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (this patient meets all three). Option A is incorrect because INR is irrelevant for DOAC dosing and renal adjustment is clearly needed. Option C is dangerously incorrect as increasing the dose would significantly increase bleeding risk in a patient with reduced clearance. Option D is inappropriate because rivaroxaban 20 mg daily would also require dose adjustment in severe renal impairment and unnecessary switching increases risk. The clinical pearl is to remember the "2 of 3" rule for apixaban dose reduction and that DOACs accumulate in renal impairment, requiring careful dose adjustment to balance stroke prevention with bleeding risk.
  15. A 57-year-old female (weight 70 kg, height 167 cm) is started on linezolid for methicillin-resistant Staphylococcus aureus skin infection while taking serotonergic medications and develops agitation, sweating, tremor, and diarrhea. Current medications: linezolid 600 mg by mouth twice daily (day 3), venlafaxine extended-release 150 mg by mouth daily, trazodone 50 mg by mouth nightly. Vitals: temperature 38.6°C, heart rate 112 beats/min. Labs: serum creatinine 0.9 mg/dL, aspartate aminotransferase 24 U/L, alanine aminotransferase 20 U/L. Allergies: none. Therapeutic goal: treat infection while preventing serious adverse effects. Which pharmacodynamic effect is responsible for the patient's symptoms?
    Answer: Excess serotonergic activity due to monoamine oxidase inhibition by linezolid combined with serotonergic antidepressants This question evaluates the pharmacodynamic concept of drug-induced serotonin syndrome through interactions involving serotonergic pathways. The key patient-specific factor is the concurrent use of multiple serotonergic agents, including venlafaxine and trazodone, which increase serotonin levels, compounded by linezolid's effects. Option A is the best choice as linezolid acts as a weak monoamine oxidase inhibitor, leading to excess serotonergic activity when combined with antidepressants, manifesting as agitation, sweating, tremor, diarrhea, fever, and tachycardia. Option B is incorrect because the interaction increases rather than reduces serotonin activity, and there is no competitive antagonism at receptors; option C is suboptimal as linezolid does not significantly affect venlafaxine clearance, and symptoms align with toxicity rather than withdrawal. Option D is wrong because while QT prolongation can occur, it does not primarily cause diarrhea, and torsades de pointes typically presents with arrhythmias, not the observed serotonergic symptoms. A transferable pearl is to screen for serotonergic drug interactions using tools like the Hunter Serotonin Toxicity Criteria. In practice, discontinue the offending agents promptly and provide supportive care, such as benzodiazepines for agitation, while avoiding further serotonergic enhancers.
  16. Renal function declines but Vd is unchanged. How should IV drug dosing be adjusted?
    Answer: Lower maintenance dose only Renal function decline lowers clearance, and maintenance dosing is based on clearance, so you cut the maintenance dose. Loading dose depends only on Vd, which is unchanged, so it stays the same. Lowering both doses is tempting because renal failure suggests dose reduction everywhere, but the loading dose doesn't need adjustment.
  17. A 67-year-old female (weight 66 kg, height 164 cm) with heart failure and edema is on furosemide but has minimal diuresis. Current medications: furosemide 40 mg by mouth twice daily, spironolactone 25 mg by mouth daily, ibuprofen 600 mg by mouth three times daily (started 1 week ago for arthritis). Labs: serum creatinine 1.5 mg/dL (baseline 1.1 mg/dL), potassium 4.6 mEq/L, aspartate aminotransferase 21 U/L, alanine aminotransferase 19 U/L. Allergies: none. Therapeutic goal: improve diuresis and reduce edema without worsening renal function. Which pharmacodynamic effect is responsible for the patient's symptoms?
    Answer: Nonsteroidal anti-inflammatory drug inhibition of prostaglandins reduces renal blood flow and blunts loop diuretic response This question tests the pharmacodynamic concept of prostaglandin-mediated renal effects on diuretic efficacy. The key patient-specific factor is the patient's heart failure with edema, where NSAID use impairs renal perfusion. Nonsteroidal anti-inflammatory drug inhibition of prostaglandins reduces renal blood flow and blunts loop diuretic response is the best choice as it explains diuretic resistance from ibuprofen counteracting furosemide's natriuretic effects. Spironolactone inhibiting furosemide competitively is false; furosemide inducing cyclooxygenase is incorrect; ibuprofen increasing bioavailability causes overdiuresis is opposite. A transferable clinical pearl is NSAIDs can reduce loop diuretic efficacy by 20-50% in HF patients. Decision frameworks include preferring acetaminophen for pain and monitoring weight/urine output for diuretic response.
  18. A 69-year-old male (weight 74 kg, height 175 cm) with bipolar disorder and chronic kidney disease is seen in clinic for tremor, nausea, and new confusion. Current medications: lithium carbonate 900 mg/day by mouth in divided doses, hydrochlorothiazide 25 mg by mouth daily (started 2 weeks ago), ibuprofen 400 mg by mouth three times daily as needed (used daily for back pain). Labs: serum creatinine 1.9 mg/dL (baseline 1.4 mg/dL), sodium 132 mEq/L, aspartate aminotransferase 22 U/L, alanine aminotransferase 18 U/L; lithium level 1.8 mEq/L (goal 0.6–1.2 mEq/L). Allergies: none. Therapeutic goal: symptom control with lithium in therapeutic range. Which drug interaction is most likely affecting the patient's drug levels?
    Answer: Hydrochlorothiazide decreases lithium clearance, increasing lithium concentration This question tests the pharmacokinetic concept of drug-drug interactions affecting renal clearance. The key patient-specific factor is the patient's chronic kidney disease with elevated serum creatinine of 1.9 mg/dL, exacerbating lithium accumulation when clearance is further reduced. Hydrochlorothiazide decreases lithium clearance, increasing lithium concentration is the best choice as it explains the toxicity symptoms and elevated level due to thiazide-induced sodium depletion enhancing lithium reabsorption. Ibuprofen inducing lithium metabolism is incorrect as NSAIDs actually decrease lithium clearance; lithium decreasing hydrochlorothiazide absorption lacks evidence; hydrochlorothiazide increasing lithium secretion is opposite to the true interaction. A transferable clinical pearl is that lithium has a narrow therapeutic index, requiring level monitoring with interacting drugs like diuretics or NSAIDs. Decision frameworks include adjusting lithium dose empirically by 25-50% downward when starting thiazides and checking levels within 5-7 days.
  19. A 54-year-old male (weight 86 kg, height 175 cm) with a kidney transplant is on tacrolimus and presents with tremor and elevated blood pressure. Current medications: tacrolimus 4 mg by mouth twice daily, mycophenolate mofetil 1000 mg by mouth twice daily, prednisone 5 mg by mouth daily; he started grapefruit juice daily 1 week ago. Labs: tacrolimus trough 18 ng/mL (goal 5–12 ng/mL), serum creatinine 1.9 mg/dL (baseline 1.4 mg/dL), aspartate aminotransferase 28 U/L, alanine aminotransferase 25 U/L. Allergies: none. Therapeutic goal: prevent rejection while avoiding tacrolimus toxicity. Which drug interaction is most likely affecting the patient's drug levels?
    Answer: Grapefruit juice inhibits intestinal CYP3A4/P-glycoprotein, increasing tacrolimus concentrations This question tests the pharmacokinetic concept of intestinal enzyme and transporter inhibition. The key patient-specific factor is the patient's post-transplant immunosuppression, making tacrolimus levels sensitive to dietary changes. Grapefruit juice inhibits intestinal CYP3A4/P-glycoprotein, increasing tacrolimus concentrations is the best choice as it explains toxicity and elevated trough from reduced first-pass metabolism. Grapefruit inducing hepatic CYP3A4 is opposite; prednisone inhibiting absorption is false; mycophenolate inducing metabolism is incorrect. A transferable clinical pearl is grapefruit can increase tacrolimus AUC by 200%, requiring avoidance. Monitoring strategies include weekly trough levels during changes, targeting based on time post-transplant.
  20. Clearance is 30 L/h; half-life is 6 h. What is the approximate volume of distribution?
    Answer: 260 L Half-life = 0.693 x Vd / CL, so Vd = CL x t1/2 / 0.693. Plug in: 30 x 6 / 0.693 = 180 / 0.693 = about 260 L. The tempting wrong answer is 180 L, which is CL times half-life without dividing by 0.693.

Start this quiz